Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice

Study Overview
=================
Brief Summary
-----------------
To compare retention rates of adalimumab, etanercept and infliximab as first-line biotherapy in rheumatoid arthritis (RA), to determine causes of discontinuation, retention-associated factors, and retention rates of possible second-line tumor necrosis factor α inhibitors (TNFi).

Detailed Description
-----------------
In this retrolective, multicentric study, medical charts of RA patients starting TNFi between March 2005 and April 2009 were reviewed, with follow-up between 2 and 6 years. The retention rate was estimated using the Kaplan-Meier method. Comparison between TNFi was done after adjustment using a Cox model. Factors associated with better retention were identified by multivariate analysis. Medical charts of all patients with RA starting a first TNFα inhibitor therapy between March 1, 2005 (start of commercialization of adalimumab in France) and April 30, 2009 (allowing at least 2 years of follow-up) were systematically reviewed in detail by 2 rheumatologist investigators

Official Title
-----------------
Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice

Conditions
-----------------
Rheumatoid Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: RA defined by the 1987 ACR criteria [18] first TNFα inhibitor prescribed in the previously mentioned period TNFα inhibitor prescribed as first-line biotherapy undergone at least one evaluation in the center after treatment initiation Exclusion Criteria: previously received another biotherapy TNFα inhibitor was prescribed in an RCT refused to participate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Etanercept<br>Etanercept: administered as first line biotherapy in RA during the period of the study | |
| Adalimumab<br>Adalimumab: administered as first line biotherpy in RA during the period of the study | |
| Infliximab<br>Infliximab: administered as first line biotherpy in RA during the period of the study | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare retention rates of adalimumab, etanercept and infliximab administered as first-line biologic therapy in RA |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare retention rates of TNFα inhibitor monoclonal antibodies (adalimumab and infliximab) and the soluble receptor (etanercept) |  | 4 years | 
| Causes of discontinuing these treatments |  | 4 years | 
| Determine the factors associated with better retention of the first TNFα inhibitors |  | 4 years | 
| Compare retention rates of possible second-line TNFα inhibitors |  | 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
retrospective study, Retention Rates, of Adalimumab, Etanercept and Infliximab, as First and Second-Line Biotherapy, in Patients with Rheumatoid Arthritis, in Daily Practice., biotherapy, TNF inhibitors